iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors

被引：0
|
作者：
Park, Wungki [1 ]
Florou, Vaia [1 ]
Algaze, Sandra [1 ]
Saravia, Diana [1 ]
Kwon, Deukwoo [1 ,2 ]
Lopes, Gilberto [1 ]
机构：
[1] Univ Miami, Miami, FL USA
[2] Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis
    Wei Liu
    Qian Zhang
    Tiantian Zhang
    Li Li
    Chunhua Xu
    World Journal of Surgical Oncology, 20
  • [32] Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
    Malhotra, Jyoti
    Huang, Amy
    Amini, Arya
    Lee, Percy
    CANCERS, 2024, 16 (21)
  • [33] Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
    Pillai, Rathi
    Behera, Madhusmita
    Owonikoko, Taofeek
    Kamphorst, Alice
    Pakkala, Suchita
    Belani, Chandra
    Khuri, Fadlo
    Ahmed, Rafi
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S253 - S254
  • [34] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    LUNG CANCER, 2016, 99 : 79 - 87
  • [35] Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
    Pillai, Rathi Narayana
    Behera, Madhusmita
    Owonikoko, Taofeek Kunle
    Kamphorst, Alice O.
    Pakkala, Suchita
    Belani, Chandra Prakash
    Khuri, Fadlo Raja
    Ahmed, Rafi
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] PD-1 and PD-L1 Inhibitors: Activity as Single Agents and Potential Biomarkers in Non-Small Cell Lung Cancer
    Goldberg, Sarah B.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (09) : 10 - 13
  • [37] Patterns of disease progression in advanced non-small cell lung cancer patients treated with PD-1 inhibitors
    Qin, Angel
    Kalemkerian, Gregory Peter
    Schneider, Bryan J.
    Hassan, Khaled Aref
    Cease, Kemp Bailey
    Zhao, Lili
    Warren, Edus H.
    Ramnath, Nithya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [39] Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
    Chen, Jianing
    Wen, Yaokai
    Chu, Xiangling
    Liu, Yuzhi
    Su, Chunxia
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
    Park, S. E.
    Kim, Y.
    Kim, H. K.
    Lee, H.
    Cho, J. H.
    Lim, S. W.
    Lee, S.
    Ahn, J. S.
    Park, K.
    Ahn, M.
    Sun, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2425 - S2425
12345